Cellares is an Integrated Development and Manufacturing Organization (IDMO) focused on the automated, large-scale manufacture of cell therapies for biopharmaceutical partners. The company develops fully automated, cGMP-compliant manufacturing and quality-control platforms—Cell Shuttle™ for end-to-end production and Cell Q™ for in-process and release testing—and builds Smart Factory networks to increase throughput, consistency, and reduce per-patient costs.
Estimated Valuation
Powered by
Leadership & Board
- Current Number of Employees
- 314
- Current LinkedIn Followers
- 33,091
Latest Estimated Valuation
- Total Amount Raised
- $257M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $257M
- Latest Funding Round
- Series D
Employee Trend
Cellares had 314 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Cellares had 33,091 followers as of October 26, 2026. The number of followers increased by 59 (0.18%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 28, 2026 | Series D | $257.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Intuitive Ventures | Series D |
| BlackRock | Series D |
| Eclipse | Series D |
| Baillie Gifford | Series D |
| DFJ Growth | Series D |
| Gates Frontier | Series D |
| EDBI | Series D |
| T. Rowe Price Investment Management, Inc. | Series D |
Similar Companies
A snapshot of private companies similar to Cellares, helping you discover and navigate related company profiles.
Related News and Analysis
